What Galderma’s nemolizumab phase II data mean for the competitive biologic landscape in pediatric eczema
Galderma’s nemolizumab phase II data in children aged 2-11 show 52-week itch and lesion relief. Read the analysis.
Why Kardigan’s Phase 2 tonlamarsen results matter more for acute severe hypertension than chronic blood pressure care
Kardigan’s tonlamarsen showed Phase 2 promise in hypertension, but can it win in acute severe hypertension next? Read the deeper analysis.
What Anumana’s FDA-cleared pulmonary hypertension algorithm means for cardiovascular AI
Anumana won FDA clearance for an ECG-AI pulmonary hypertension tool. Read what it changes for diagnosis, workflow adoption, and cardiovascular AI strategy.
Novo Nordisk’s Awiqli approval could change how basal insulin is used in type 2 diabetes
Novo Nordisk’s Awiqli wins FDA approval as the first once-weekly basal insulin. Read what this could change for type 2 diabetes care.
Medtronic broadens Stealth AXiS reach as integrated surgical platforms gain strategic importance
Medtronic won FDA clearance for Stealth AXiS in cranial and ENT surgery. Read why this platform move could reshape surgical workflow competition.
How Agilent’s PD-L1 companion diagnostic now shapes pembrolizumab access in esophageal carcinoma
FDA approves Agilent’s PD-L1 IHC 22C3 pharmDx for esophageal and GEJ carcinoma, marking the eighth companion diagnostic indication alongside pembrolizumab. Read the analysis.
Can Drug Farm turn ALPK1 inhibition into the first real disease-modifying approach for ROSAH syndrome?
Drug Farm won FDA orphan drug designation for DF-003 in ROSAH syndrome. Read what this rare disease milestone could change next.
LensOne enters pivotal study as Long Bridge Medical targets a difficult gap in secondary IOL fixation
Long Bridge Medical’s LensOne has entered a pivotal FDA-cleared study. Read why this ophthalmic device trial could reshape secondary IOL fixation.
What the NEOK002 IND milestone changes for Biocytogen, NEOK Bio, and ADC competition
NEOK002 has cleared the FDA IND stage. Read why this bispecific ADC matters for solid tumors, clinical strategy, and the next phase of ADC competition.
Can AbbVie’s Juvéderm strategy turn subtle aesthetics into the next growth engine for fillers
AbbVie is repositioning Juvéderm for the “undetectable” aesthetics era. Read what this means for injectables, clinicians, and market competition.